Loading
companiesCompany
Ambrx
Ambrx is a La Jolla, California biotechnology company founded in 2003 whose HER2 antibody-drug conjugate ARX788 is in OnCo's phase 3 ACE-Breast-02 trial (with Zhejiang Medicine, in China) and the global phase 2 ACE-Breast-03 trial after trastuzumab deruxtecan.
Also called: Ambrx, Inc.Ambrx IncAmbrx Biopharma
Overview
Ambrx is an organisation based in La Jolla, United States, founded in 2003 (Wikidata Q100955904, which also gives its website). ClinicalTrials.gov classes it as an industry sponsor. In OnCo it sponsors ACE-Breast-02 (phase 3, with Zhejiang Medicine: ARX788 against lapatinib plus capecitabine in HER2-positive advanced breast cancer after trastuzumab and a taxane, recorded as positive) and NCT04829604 (ACE-Breast-03, phase 2, ARX788 in HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan). ARX788 is its own compound, the basis for the biotech type.
Headquarters
La Jolla, California, US
Scorecard
All companies#310of 1244 companies, score 13
- phase 3 +3
- targets +2
- modalities +2
- registry trials +6
0 approved, 1 in phase 3, 0 earlier, 1 targets, 10 registry studies. Formula on the scorecards page.
Type
Website
Founded
2003
Phase 3ADC
ARX788 is a HER2 ADC with a precisely placed, non-cleavable payload that beat lapatinib-capecitabine in China and showed activity in brain metastases.
Similar pages
- CompanyCriterium
Shares HER2-positive breast cancer and the tag wave5-sponsor.
- TechnologySite-specific conjugation & linker chemistry
Shares ACE-Breast-02, ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03), ARX788, HER2-positive breast cancer.
- IdeaSequencing HER2 ADCs by payload after T-DXd
Shares ARX788, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
- TreatmentLapatinib
Shares ACE-Breast-02, HER2, HER2-positive breast cancer.
cancers
technologies
targets
drugs
Phase 3ADC